1. Erythropoietin treatment and osteoporotic fracture risk in hemodialysis patients: A nationwide population-based study
- Author
-
Ching-Yu Lee, Fung-Chang Sung, Peir-Haur Hung, Chih-Hsin Muo, Meng-Huang Wu, Tsung-Jen Huang, and Chih-Ching Yeh
- Subjects
Erythropoietin ,End-stage renal disease ,Hemodialysis ,Osteoporotic fracture risk ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Objectives: Concerns about erythropoietin (EPO) therapy for anemia in patients with end-stage renal disease (ESRD) contributing to potential bone loss and increased fracture risks are growing. This study investigated the impact of EPO administration on the risk of common osteoporotic fractures in ESRD patients. Methods: This population-based retrospective cohort study compared EPO users and non-EPO users among ESRD patients undergoing hemodialysis, diagnosed with ESRD between 2000 and 2014 identified from the National Health Insurance Research Database of Taiwan. The cohorts were matched at a propensity score ratio of 1:1, resulting in equal sample sizes of 2839. Variables related to comorbidities were considered. Results: EPO users exhibited higher cumulative incidences of major osteoporotic fractures, hip fractures, spine fractures, and wrist fractures compared with the non-EPO user (all P
- Published
- 2024
- Full Text
- View/download PDF